Medasense offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication.
Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedicationMedasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and a proprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market.The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing.Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 7, 2013 | Series A | $4.50M | 2 | Medoc AMS LGL Capital Pty Ltd | — | Detail |
Dec 1, 2008 | Series Unknown | $1M | 2 | Capital Point | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Medoc AMS | Yes | Series A |
LGL Capital Pty Ltd | Yes | Series A |
Capital Point | Yes | Series Unknown |
Ofakim Hi-Tech Ventures | — | Series Unknown |